
Cancer. The body changes. The terrain changes. The rules change. Making sense of biological shifts in remission through lived experience and structured reasoning.
| Platform | Pricing | Only free issues | Publishes | Daily | |
|---|---|---|---|---|---|
| Issues | 21 | Founded | 3 months ago | Last Issue | 4 days ago |
| Active | |||||

Most people who take zinc never realize they are changing another mineral at the same time.
That mineral is copper.
And copper is one of the few minerals many tumors appear to depend on.
Zinc is one of the most common supplements in canc...
Extracted from magnolia bark, honokiol is one of the few natural compounds studied for both brain penetration and cancer stem cell biology.
Even though I’m in remission, the possibility of relapse is never completely out of my mind.
The b...
Ferritin may be one of the most misunderstood blood markers in cancer.
Patients are told to lower it, raise it, ignore it or fear it, often without much explanation of what it actually reflects.
A doctor once told me his ferritin came bac...
Cancer patients get a lot of blood drawn.
Results come back. A number gets flagged or it doesn’t. Someone says “looks fine”, or they point to one number, and then the appointment moves on.
By the time most patients learn what RDW, NLR or...
Surprising new studies have just come out suggesting that GLP-1 drugs may reduce metastasis in cancer patients.
That is the kind of news that stops you in your tracks. The implications here reach far beyond the public conversation around w...
Subscribers, engagement, traffic and sponsorship for The Cancer Strategist.
| Subscribers | Engagement | 79 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
The writers behind this newsletter.
Integrative cancer strategies: what works, what doesn’t, and what can backfire. MSc, analyst — I look at what the research says and what life actually teaches. From diagnosis to remission, I’m tracking this in real time.
You can find recent issues that have been published by The Cancer Strategist on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The Cancer Strategist, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Cancer Strategist as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Cancer Strategist using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Related Newsletters to see other publications like The Cancer Strategist. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.